Cullinan will present new preclinical data for CLN-978 and details of a Phase 1b study in lupus at ACR 2024.
Quiver AI Summary
Cullinan Therapeutics, Inc. announced that it will present new preclinical data for its novel CD19xCD3 T cell engager, CLN-978, at the ACR Convergence 2024 conference in Washington, D.C. on November 16, 2024. The presentation will focus on the results of a global Phase 1b study aimed at treating moderate to severe systemic lupus erythematosus (SLE). The new data demonstrate that CLN-978 is effective in activating T cells, depleting B cells, and producing cytokines in patients with SLE and rheumatoid arthritis, suggesting its potential for a broad therapeutic index. With regulatory approvals in the U.S. and Australia, the company is set to launch the Phase 1b clinical trial, which will evaluate the drug's safety and effectiveness in patients who have not responded adequately to standard treatments. An in-person investor event will also take place on the same day to discuss the data and the drug's development path.
Potential Positives
- Cullinan is presenting promising new in vitro preclinical data for CLN-978 that enhances the rationale for its clinical development in autoimmune diseases, including systemic lupus erythematosus (SLE).
- The company is launching a global Phase 1b clinical trial for CLN-978 following regulatory clearances from the U.S. FDA and Australia's Human Research Ethics Committee, indicating strong progress in their development efforts.
- CLN-978 is designed for convenient subcutaneous delivery and demonstrates significant B cell depletion, suggesting its potential as a new therapeutic option for patients with autoimmune diseases.
- An in-person investor event is scheduled, offering an opportunity for direct engagement with company leadership and fostering transparency with stakeholders.
Potential Negatives
- Despite the presentation of new preclinical data, initial clinical data for CLN-978 are not expected until the fourth quarter of 2025, indicating a lengthy timeline before any potential market introduction.
- The Phase 1b study requires patients with moderate to severe systemic lupus erythematosus to have had an inadequate response to at least two treatments, suggesting that current treatment options may be limited or ineffective for these patients, which could reflect poorly on the company’s confidence in the drug.
FAQ
What is CLN-978?
CLN-978 is a novel CD19xCD3 bispecific T cell engager designed for treating autoimmune diseases such as systemic lupus erythematosus.
When will Cullinan present the new preclinical data?
Cullinan will present the new preclinical data at ACR Convergence 2024 on November 16, 2024, from 10:30 a.m. to 12:30 p.m. ET.
What is the purpose of the CLN-978 Phase 1b study?
The Phase 1b study aims to evaluate the safety and efficacy of CLN-978 in patients with moderate to severe systemic lupus erythematosus.
How can investors attend the Cullinan investor event?
Investors can register for the event by emailing Nick Smith at [email protected] to attend in person on November 16, 2024.
What are the key objectives of the Phase 1b study?
The primary objective is to evaluate the safety of CLN-978, with secondary objectives including pharmacokinetics and clinical activity assessment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CGEM Insider Trading Activity
$CGEM insiders have traded $CGEM stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $CGEM stock by insiders over the last 6 months:
- JENNIFER MICHAELSON (Chief Scientific Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 24,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CGEM Hedge Fund Activity
We have seen 100 institutional investors add shares of $CGEM stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BVF INC/IL added 2,553,982 shares (+79.9%) to their portfolio in Q2 2024
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 2,141,706 shares (+188.1%) to their portfolio in Q2 2024
- ALLIANCEBERNSTEIN L.P. added 1,695,345 shares (+5106.5%) to their portfolio in Q2 2024
- AVIDITY PARTNERS MANAGEMENT LP added 1,559,826 shares (+inf%) to their portfolio in Q2 2024
- VR ADVISER, LLC added 1,379,965 shares (+inf%) to their portfolio in Q2 2024
- HOLOCENE ADVISORS, LP added 1,316,005 shares (+inf%) to their portfolio in Q2 2024
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,282,829 shares (+135.0%) to their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
